Enhanced levels of glutathione and protein glutathiolation in rat tongue epithelium during 4-NQO-induced carcinogenesis

International Journal of Cancer

Volumn 120, Issue 7, 2007, Pages 1396-1401

  Huang, Zhishan ^a   Komninou, Despina ^b   Kleinman, Wayne ^c   Pinto, John T ^c   Gilhooly, Elaine M ^b   Calcagnotto, Ana ^b   Richie Jr , John P ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

4 nitroquinolin N oxide; Glutathione; Oral cancer; Protein glutathiolation

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CELL PROTEIN; GLUTATHIONE; GLUTATHIONE DISULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; HISTOPATHOLOGY; MALE; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLUTATHIOLATION; PROTEIN MODIFICATION; RAT; SQUAMOUS CELL CARCINOMA; TONGUE; TONGUE CANCER;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; CARCINOGENS; CARCINOMA IN SITU; EPITHELIUM; FOCAL EPITHELIAL HYPERPLASIA; GLUTATHIONE; LIVER; MALE; NEOPLASM PROTEINS; RATS; RATS, INBRED F344; SULFHYDRYL COMPOUNDS; TONGUE NEOPLASMS;

EID: 33847618300     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22525     Document Type: Article

References (79)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hoffmann D, Hecht SS. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res 1985;45:935-44.
3. Mignogna MD, Fedele S, Lo Russo L, Ruoppo E, Lo Muzio L. Oral and pharyngeal cancer: lack of prevention and early detection by health care providers. Eur J Cancer Prev 2001;10:381-3.
4. Yancik R. Frames of reference: old age as the context for prevention and treatment of cancer. In: Yanick R, ed. Perspectives on prevention and treatment of cancer in the elderly. New York: Raven Press, 1983.
5. Richie JP, Jr. The role of nutrition in cancer of the oral cavity. J Appl Nutr 1991;43:49-57.
6. Stich HF, Anders F. The involvement of reactive oxygen species in oral cancers of betel quid/tobacco chewers. Mutat Res 1989;214:47-61.
7. Subapriya R, Kumaraguruparan R, Ramachandran CR, Nagini S. Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem 2002;35:489-93.
8. Zain RB. Cultural and dietary risk factors of oral cancer and precancer-a brief overview. Oral Oncol 2001;37:205-10.
9. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
10. Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-65.
11. Droge W. Oxidative stress and aging. Adv Exp Med Biol 2003;543:191-200.
12. Reichart PA. Identification of risk groups for oral precancer and cancer and preventive measures. Clin Oral Investig 2001;5:207-13.
13. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-92.
14. Locigno R, Castronovo V. Reduced glutathione system: role in cancer development, prevention and treatment (review). Int J Oncol 2001;19:221-36.
15. Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988;202:343-61.
16. Hamilos DL, Wedner HJ. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-l-one by nuclear size transformation. J Immunol 1985;135:2740-7.
17. Richie JP, Jr. The role of glutathione in aging and cancer. Exp Gerontol 1992;27:615-26.
18. Flagg EW, Coates RJ, Jones DP, Byers TE, Greenberg RS, Gridley G, McLaughlin JK, Blot WJ, Haber M, Preston-Martin S, Schoenberg JB, Austin DF, et al. Dietary glutathione intake and the risk of oral and pharyngeal cancer. Am J Epidemiol 1994;139:453-65.
19. Trickier D, Shklar G, Schwartz J. Inhibition of oral carcinogenesis by glutathione. Nutr Cancer 1993;20:139-44.
20. Schwartz JL, Shklar G. Glutathione inhibits experimental oral carcinogenesis, p53 expression, and angiogenesis. Nutr Cancer 1996;26:229-36.
21. Shklar G, Schwartz J, Trickier D, Cheverie SR. The effectiveness of a mixture of β-carotene, α-tocopherol, glutathione, and ascorbic acid for cancer prevention. Nutr Cancer 1993;20:145-51.
22. Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochem Funct 2004;22:343-52.
23. Wong DY, Hsiao YL, Poon CK, Kwan PC, Chao SY, Chou ST, Yang CS. Glutathione concentration in oral cancer tissues. Cancer Lett 1994;81:111-16.
24. Guichard M, Lespinasse F, Estelin R, Gerbaulet A, Haie C, Lartigau E, Malaise EP, Micheau C, Prade M, Richard JM. Glutathione and cysteine levels in human tumour biopsies. Br J Radiol 1990;63:557-61.
25. Parise O, Jr, Janot F, Luboinski B, Massaad L, Albin N, Toussaint C, Verjus MA, Bonnay M, Gouyette A, Chabot GG. Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head Neck 1994;16:158-64.
26. Saroja M, Balasenthil S, Nagini S. Tissue lipid peroxidation and glutathione-dependent enzyme status in patients with oral squamous cell carcinoma. Cell Biochem Funct 1999;17:213-16.
27. Zhang L, Mock D. Alteration in glutathione level during carcinogenesis of hamster buccal pouch mucosa. J Dent Res 1991;70:1061-3.
28. Nathan CF, Arrick BA, Murray HW, DeSantis NM, Cohn ZA. Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med 1981;153:766-82.
29. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993;72:783-7.
30. Lee FY, Vessey A, Rofstad E, Siemann DW, Sutherland RM. Heterogeneity of glutathione content in human ovarian cancer. Cancer Res 1989;49:5244-8.
31. Cook JA, Pass HI, Iype SN, Friedman N, DeGraff W, Russo A, Mitchell JB. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 1991;51:4287-94.
32. Kudo H, Mio T, Kokunai T, Tamaki N, Sumino K, Matsumoto S. Quantitative analysis of glutathione in human brain tumors. J Neurosurg 1990;72:610-15.
33. Mitchell JB, Biaglow JE, Russo A. Role of glutathione and other endogenous thiols in radiation protection. Pharmacol Ther 1988;39:269-74.
34. Kang YJ, Enger MD. Glutathione content and growth in A549 human lung carcinoma cells. Exp Cell Res 1990;187:177-9.
35. Kang YJ, Feng Y, Hatcher EL. Glutathione stimulates A549 cell proliferation in glutamine-deficient culture: the effect of glutamate supplementation. J Cell Physiol 1994;161:589-96.
36. Hall AG. Review: the role of glutathione in the regulation of apoptosis. Eur J Clin Invest 1999;29:238-45.
37. Cotgreave IA, Gerdes RG. Recent trends in glutathione biochemistry-glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? Biochem Biophys Res Commun 1998;242:1-9.
38. Klatt P, Lamas S. Regulation of protein function by S- glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000;267:4928-44.
39. Sies H, Brigelius R, Graf P. Hormones, glutathione status and protein S-thiolation. Adv Enzyme Regul 1987;26:175-89.
40. Giustarini D, Rossi R, Milzani A, Colombo R. Dalle-Donne I. S-glutathionylation: from redox regulation of protein functions to human diseases. J Cell Mol Med 2004;8:201-12.
41. Ward NE, Stewart JR, Ioannides CG, O'Brian CA. Oxidant-induced S-glutathiolation inactivates protein kinase C-α (PKC-α): a potential mechanism of PKC isozyme regulation. Biochemistry 2000;39:10319-29.
42. Mallis RJ, Buss JE, Thomas JA. Oxidative modification of H-ras: S-thiolation and S-nitrosylation of reactive cysteines. Biochem J 2001;355:145-53.
43. Caplan JF, Filipenko NR, Fitzpatrick SL, Waisman DM. Regulation of annexin A2 by reversible glutathionylation. J Biol Chem 2004;279:7740-50.
44. Obin M, Shang F, Gong X, Handelman G, Blumberg J, Taylor A. Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights using the thiol-specific oxidant diamide. FASEB J 1998;12:561-9.
45. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 2002;99:9745-9.
46. Klatt P, Molina EP, Lamas S. Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation. J Biol Chem 1999;274:15857-64.
47. Klatt P, Molina EP, De Lacoba MG, Padilla CA, Martinez-Galesteo E, Barcena JA, Lamas S. Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J 1999;13:1481-90.
48. Cao X, Kambe F, Lu X, Kobayashi N, Ohmori S, Seo H. Glutathionylation of two cysteine residues in paired domain regulates DNA-binding activity of Pax-8. J Biol Chem 2005;280:25901-6.
49. Humphries KM, Deal MS, Taylor SS. Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification. J Biol Chem 2005;280:2750-8.
50. Cross JV, Templeton DJ. Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain. Biochem J 2004;381:675-83.
51. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP. Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J Biol Chem 2003;278:19603-10.
52. Tanaka T. Chemoprevention of oral carcinogenesis. Eur J Cancer B Oral Oncol 1995;31:3-15.
53. Richie JP, Jr, Skowronski L, Abraham P, Leutzinger Y. Blood glutathione concentrations in a large-scale human study. Clin Chem 1996;42:64-70.
54. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications 10 mammalian blood and other tissues. Anal Biochem 1969;27:502-22.
55. Kleinman WA, Richie JP, Jr. Determination of thiols and disulfides using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995;672:73-80.
56. Kleinman WA, Komninou D, Leutzinger Y, Colosimo S, Cox J, Lang CA, Richie JP, Jr. Protein glutathiolation in human blood. Biochem Pharmacol 2003;65:741-6.
57. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989;264:13963-4.
58. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
59. Peklak-Scott C, Townsend AJ, Morrow CS. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione S-transferase, and MRP1. Biochemistry 2005;44:4426-33.
60. Wattenberg LW. Inhibition of chemical carcinogens by minor dietary components. In: Aronott MS, Eys J, Wang Y, eds. Molecular interactions of nutrition and cancer. New York: Raven Press, 1976:5-17.
61. Ip C. Prophylaxis of mammary neoplasia by selenium supplementation in the initiation and promotion phases of chemical carcinogenesis. Cancer Res 1981;41:4386-90.
62. De Flora S, Bennicelli C, Camoirano A, Serra D, Romano M, Rossi GA, Morelli A, De Flora A. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 1985;6:1735-45.
63. de Vries N, van Zandwijk N, Pastorino U. Chemoprevention in the management of oral cancer: EUROSCAN and other studies. Eur J Cancer B Oral Oncol 1992;28:153-7.
64. Pereira MA, Khoury MD. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett 1991;61:27-33.
65. Balasenthil S, Nagini S. Inhibition of 7,12-dimethylbenz[a]anthracene- induced hamster buccal pouch carcinogenesis by S-allylcysteine. Oral Oncol 2000;36:382-6.
66. Rotstein JB, Slaga TJ. Effect of exogenous glutathione on tumor progression in the murine skin multistage carcinogenesis model. Carcinogenesis 1988;9:1547-51.
67. Novi AM. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. Science 1981;212:541-2.
68. Evans SM, Lew R, Kochman ML, Wileyto EP, Baum E, Safford KM, Koch CJ. Human esophageal cancer is distinguished from adjacent esophageal tissue by tissue cysteine concentrations. Dig Dis Sci 2002;47:2743-50.
69. Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, Bannai S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer 2003;88:951-6.
70. Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT. Increase in γ-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 1992;52:5115-18.
71. Mulcahy RT, Bailey HH, Gipp JJ. Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistani human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 1994;34:67-71.
72. Soini Y, Napankangas U, Jarvinen K, Kaarteenaho-Wiik R, Paakko P, Kinnula VL. Expression of γ-glutamyl cysteine synthetase in nonsmall cell lung carcinoma. Cancer 2001;92:2911-19.
73. Tatebe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, Kuo MT. Expression of heavy subunit of γ-glutamylcysteine synthetase (γ-GCSh) in human colorectal carcinoma. Int J Cancer 2002;97:21-7.
74. Jarvinen K, Soini Y, Kahlos K, Kinnula VL. Overexpression of γ-glutamylcysteine synthetase in human malignant mesothelioma. Hum Pathol 2002;33:748-55.
75. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-14.
76. Vanderlaan M, Phares W. γ-Glutamyltranspeptidase: a tumour cell marker with a pharmacological function. Histochem J 1981;13:865-77.
77. Zhang L, Mock D. γ-Glutamyl transpeptidase activity in superficial exfoliated cells during hamster buccal pouch carcinogenesis. Carcinogenesis 1989;10:857-60.
78. Mock D, Whitestone B, Freeman J. γ-Glutamyl transpeptidase activity in human oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol 1987;64:197-201.
79. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996;32:967-78.